NOV 09, 2017 10:00 AM PST

Eliminating inherent genome editing bottlenecks in iPSCs to build physiologically relevant disease models

Speakers
  • Staff Scientist, Thermo Fisher Scientific
    Biography
      Dr. Erik Willems was trained as a stem cell biologist in Brussels, Belgium where he obtained his PhD in 2007, after which he soon relocated to San Diego, California to develop his expertise in the use of pluripotent stem cells in high throughput screening assays for understanding the basic biology and disease of the developing heart at the Sanford Burnham Prebys Medical Discovery Institute. Dr. Willems then pursued his passion for the development of biotechnology tools and applications and joined Thermo Fisher Scientific in Carlsbad, California where he - as a Manager in the Cell Biology group - currently leads a team focused on pluripotent stem cell-based customer driven projects and product applications, including characterization, reprogramming, genome editing, differentiation and disease modeling with a focus on drug discovery applications. Now in the stem cell field for over 15 years, Dr. Willems published numerous peer reviewed articles including in high impact journals such as Cell Stem Cell. His key expertise includes pluripotent stem cell biology, differentiation, genome editing, high throughput screening and drug discovery.

    Abstract:

    Therapeutic development for human diseases continues to face obstacles, particularly in translating targets or compounds identified by in vitro screening campaigns to valid targets or efficacious and safe compounds once tested in humans.  Here we discuss strategies that leverage induced pluripotent stem cells (iPSCs) to increase the relevance of human cell models for these in vitro approaches.  We review current advances in genome engineering to pivot from challenges with delivery, identification and selection and subsequent clonal outgrowth by leveraging tools to consistently and reliably generate knock-out and knock-in models for use in target or compound identification.  Specifically, we demonstrate this approach with iPSCs to build isogenic disease models, which can be further differentiated to various cell types of interest such as cardiomyocytes and dopaminergic neurons to model disease and are more directly related to a disease area than commonly used immortalized cell lines.  We expect strategies combining genome engineering and stem cells to provide platforms for more robust disease models that will provide more predictable translation of in vitro to in vivo results.


    Show Resources
    You May Also Like
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUN 05, 2019 05:00 PM CEST
    C.E. CREDITS
    JUN 05, 2019 05:00 PM CEST
    DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2019 07:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    MAY 23, 2019 09:00 AM PDT
    C.E. CREDITS
    MAY 23, 2019 09:00 AM PDT
    DATE:  May 23, 2019TIME:   9:00am PDT, 12:00pm EDT Although mesenchymal stem/stromal cells (MSCs) chondrogenic differentiation has been thoroughly investigated...
    Loading Comments...
    Show Resources